Previous reports linked MeCP2 expression with ER status (3) and with BRCA1 promoter silencing (120), which provided further rationale for assessing genome-wide MeCP2 profiling in both MCF7 and MDA-MB-468 cells, which represent two subtypes of breast cancer. This evidence concerns the gene BRCA1 and breast cancer.